Shareholding disclosure

Thomas Meier

Declared position

Threshold

Fell below threshold

Timeline

Published

17.09.2015

Transaction

09.09.2015

Voting rights breakdown

Voting rights acquired0%

Voting rights sold0%

Below threshold3%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAF9E00026

Beneficial owner

Thomas Meier

Declared address

Thomas Meier, 4056 Basel

Exercise of stock options and sale of 70,000 shares.

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Thomas Meier

Santhera Pharmaceuticals Holding AG17.09.2015TAF9E00026

Disclosure summary

Thomas Meier disclosed a holding in Santhera Pharmaceuticals Holding AG that fell below the publication threshold, published by SIX Exchange Regulation on 17.09.2015, at 3% of voting rights. Notice category: Single shareholder.

Disclosed position

Below threshold

Voting rights acquired0%

Voting rights sold0%

Below threshold3%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Thomas Meier disclosed a holding in Santhera Pharmaceuticals Holding AG, published on 17.09.2015.

Publication date17.09.2015

Transaction date09.09.2015

Issuing companySanthera Pharmaceuticals Holding AG

Beneficial ownerThomas Meier

Declared addressThomas Meier, 4056 Basel

CategorySingle shareholder

Voting rights acquired0%

Voting rights sold0%

Below threshold3%

ExchangeXSWX

Notification IDTAF9E00026

Conditions

Exercise of stock options and sale of 70,000 shares.

Source: SIX Exchange Regulation · Publication date: 17.09.2015

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open